The decision paves the way for Enzo to be issued a patent based on its prior application, and the company plans to "rapidly" develop and market products based on the technology for a wide variety of applications.
Shares of Interleukin rose after the firm said that the results of a retrospective study suggest that individuals who base their diet on genotype could potentially benefit from the firm's weight management genetic test.
Celera posted a profit, even though its Q4 revenues declined due to lower sales from its lab services business. The firm also guided for lower 2010 revenues than the market had previously expected due to issues surrounding that part of its business.
Alnylam's top official said that while the company is encouraged that it will be able to confirm efficacy data observed in a phase IIa trial of its respiratory syncytial virus treatment ALN-RSV01, he stressed that it may not be able to do so in a follow-up study initiated late last month.
As part of its request for dismissal, MIT admitted no wrongdoing, but agreed to be bound by any court ruling against the case's other defendants, the Whitehead Institute for Biomedical Research and the University of Massachusetts Medical School.